Nyxoah S.A. (NASDAQ:NYXH)

Nyxoah S.A. NYXH

Healthcare - Medical - Instruments & Supplies - NASDAQ - BE

Watchlist

$ 8.22

-0.725 %

$ 282 M

Market Cap

-4.52

P/E

1. INTRINSIC VALUE

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.[ Read More ]

The intrinsic value of one NYXH stock under the base case scenario is HIDDEN Compared to the current market price of 8.22 USD, Nyxoah S.A. is HIDDEN

NYXH Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart NYXH

FINANCIALS

Annual
Quarterly

4.35 M REVENUE

Growth Rates

1Year 40.99%

3Years 297.94%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-45.1 M OPERATING INCOME

Growth Rates

1Year -38.78%

3Years -58.98%

5Years -39.79%

7Years 0.00%

10Years 0.00%

-44.7 M NET INCOME

Growth Rates

1Year -48.58%

3Years -54.32%

5Years -37.65%

7Years 0.00%

10Years 0.00%

-44.8 M OPERATING CASH FLOW

Growth Rates

1Year -55.72%

3Years -85.50%

5Years -40.64%

7Years 0.00%

10Years 0.00%

32 M INVESTING CASH FLOW

Growth Rates

1Year 135.59%

3Years 70.93%

5Years 236.09%

7Years 0.00%

10Years 0.00%

16.9 M FINANCING CASH FLOW

Growth Rates

1Year 1814.95%

3Years -45.51%

5Years 2.36%

7Years 0.00%

10Years 0.00%

1.27 M REVENUE

Growth Rates

1Year 40.99%

3Years 297.94%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-15 M OPERATING INCOME

Growth Rates

1Year -38.78%

3Years -58.98%

5Years -39.79%

7Years 0.00%

10Years 0.00%

-13.1 M NET INCOME

Growth Rates

1Year -48.58%

3Years -54.32%

5Years -37.65%

7Years 0.00%

10Years 0.00%

-11.3 M OPERATING CASH FLOW

Growth Rates

1Year -55.72%

3Years -85.50%

5Years -40.64%

7Years 0.00%

10Years 0.00%

-28.2 M INVESTING CASH FLOW

Growth Rates

1Year 135.59%

3Years 70.93%

5Years 236.09%

7Years 0.00%

10Years 0.00%

45.2 M FINANCING CASH FLOW

Growth Rates

1Year 1814.95%

3Years -45.51%

5Years 2.36%

7Years 0.00%

10Years 0.00%

Balance Sheet Decomposition Nyxoah S.A.

124 M ASSETS
26.1 M LIABILITIES

Current Assets	68.4 M
Cash & Short-Term Investments	57.7 M
Receivables	2.76 M
Other Current Assets	7.84 M
Non-Current Assets	55.8 M
Long-Term Investments	1.17 M
PP&E	7.98 M
Other Non-Current Assets	46.7 M

Current Liabilities	14.4 M
Accounts Payable	4.1 M
Short-Term Debt	1.22 M
Other Current Liabilities	9.13 M
Non-Current Liabilities	11.7 M
Long-Term Debt	11.5 M
Other Non-Current Liabilities	203 K

EFFICIENCY

Earnings Waterfall Nyxoah S.A.

Revenue	4.35 M
Cost Of Revenue	1.66 M
Gross Profit	2.69 M
Operating Expenses	47.8 M
Operating Income	-45.1 M
Other Expenses	-445 K
Net Income	-44.7 M

RATIOS

61.91% GROSS MARGIN

Averages

1Year 61.91%

3Years 63.02%

5Years 49.12%

7Years 35.08%

10Years 0.00%

-1037.30% OPERATING MARGIN

Averages

1Year -1037.30%

3Years -1723.72%

5Years -4287.56%

7Years -3062.54%

10Years 0.00%

-993.84% NET MARGIN

Averages

1Year -993.84%

3Years -1749.33%

5Years -4598.87%

7Years -3284.91%

10Years 0.00%

-44.04% ROE

Averages

1Year -44.04%

3Years -29.53%

5Years -59.31%

7Years -87.50%

10Years 0.00%

-34.80% ROA

Averages

1Year -34.80%

3Years -24.12%

5Years -26.17%

7Years -39.20%

10Years 0.00%

-40.85% ROIC

Averages

1Year -40.85%

3Years -28.59%

5Years -31.01%

7Years -44.46%

10Years 0.00%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Nyxoah S.A.

Net Income	-44.7 M
Depreciation & Amortization	2.36 M
Capital Expenditures	-11 M
Stock-Based Compensation	2.61 M
Change in Working Capital	-3.49 M
Others	-1.6 M
Free Cash Flow	-55.7 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Nyxoah S.A.

Wall Street analysts predict an average 1-year price target for NYXH of $19 , with forecasts ranging from a low of $15 to a high of $27 .

NYXH Lowest Price Target Wall Street Target

15 USD 82.48%

NYXH Average Price Target Wall Street Target

19 USD 131.14%

NYXH Highest Price Target Wall Street Target

27 USD 228.47%

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

0.179 USD

PDEX

Overvalued 99.61%

KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally.

-2.63 USD

KRMD

Overvalued 183.12%

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

0 USD

NXGL

Overvalued 100.00%

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.

-1.18 USD

DXR

Overvalued 113.09%

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide.

50.1 USD

LMAT

Overvalued 50.89%

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.

127 USD

UTMD

Undervalued 91.99%

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy.

42.3 USD

MMSI

Overvalued 58.49%

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally.

-18.5 USD

ATRC

Overvalued 152.82%

6. Ownership

Insider Ownership Nyxoah S.A.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price

7. News

Nyxoah S.A. (NYXH) Q3 2024 Earnings Call Transcript Nyxoah S.A. (NASDAQ:NYXH ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications and IR Manager Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Adam Maeder - Piper Sandler Joe Federico - Stifel Suraj Kalia - Oppenheimer Ross Osborn - Cantor Fitzgerald David Rescott - Baird Operator Good day. seekingalpha.com - 1 week ago

Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue Estimates Nyxoah SA (NYXH) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.29 per share a year ago. zacks.com - 1 week ago

Nyxoah Appoints John Landry as Chief Financial Officer Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. globenewswire.com - 1 week ago

Nyxoah SA (NYXH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Nyxoah (NYXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago

Publication relating to transparency notifications REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 25, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Vestal Point Capital On October 23, 2024, Nyxoah received a transparency notification from Vestal Point Capital following an acquisition or disposal of voting securities or voting rights. globenewswire.com - 3 weeks ago

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. globenewswire.com - 3 weeks ago

Publication relating to transparency notifications REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 15, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received three transparency notifications as detailed below. Jürgen Hambrecht On October 15, 2024, Nyxoah received a transparency notification from Jürgen Hambrecht and Jürgen Hambrecht's controlled undertaking JH Capital GmbH following an acquisition or disposal of voting securities or voting rights. globenewswire.com - 1 month ago

Publication relating to transparency notifications REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 9, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On October 7, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons following a change to BlackRock's group structure. globenewswire.com - 1 month ago

Nyxoah Raises $27 Million through its At-the-Market Offering INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $27 Million through its At-the-Market Offering Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus Mont-Saint-Guibert, Belgium – October 7, 2024, 11:00pm CET / 5:00pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company has sold 3.0 million shares raising $27.0 million in gross proceeds pursuant to the Company's $50 million at-the-market ("ATM") offering at a price per share equal to the market price on the Nasdaq Global Market at the time of sale. The shares were sold, based on interest received, to a single U.S.-based healthcare investor. globenewswire.com - 1 month ago

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update Additional clinical data on patients suffering from Obstructive Sleep Apnea (OSA) demonstrate a clinically significant 71.0% median reduction in Apnea-Hypopnea index (AHI) while sleeping supine at 12 months compared with baseline. 82.0% of patients who completed a polysomnography at 12 months had an AHI below 15, and 67.4% of patients who completed a polysomnography at 12 months had an AHI below 10. globenewswire.com - 1 month ago

Publication relating to transparency notifications REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 27, 2024 , 8.00am CET / 2.00am ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On September 24, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons indicating that BlackRock Advisors, LLC went below the 3% threshold on September 20, 2024. globenewswire.com - 1 month ago

Nyxoah to Participate in Upcoming Investor Conferences Nyxoah to Participate in Upcoming Investor Conferences Mont-Saint-Guibert, Belgium – September 5, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in three upcoming investor conferences in New York City. Olivier Taelman, Nyxoah's Chief Executive Officer, will deliver corporate updates at the Baird Global Healthcare Conference on Tuesday, September 10, 2024, at 12:15pm ET, the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024, at 11:00am ET and the Cantor Global Healthcare Conference on Wednesday, September 18, 2024 at 1:55pm ET. globenewswire.com - 2 months ago

8. Profile Summary

Nyxoah S.A. NYXH

COUNTRY BE

INDUSTRY Medical - Instruments & Supplies

MARKET CAP $ 282 M

Dividend Yield 0.00%

Description Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Contact Rue Edouard Belin 12, Mont-Saint-Guibert, 1435 https://www.nyxoah.com

IPO Date April 28, 2021

Employees 146

Officers Mr. Olivier Taelman Chief Executive Officer & Executive Director Mr. Robert Taub MBA Co-Founder & Chairman

Price Chart NYXH

Nyxoah S.A. NYXH

Premium Plan

Unlimited Plan